Invokana joins Forxiga in European SGLT2 inhibitor space
This article was originally published in Scrip
Executive Summary
The European Commission has approved Invokana (canagliflozin) from Janssen-Cilag (J&J) for type 2 diabetes, making it the second SGLT2 inhibitor to reach the European market after AstraZeneca/Bristol-Myers Squibb's Forxiga (dapagliflozin) was approved a year ago (scripintelligence.com, 15 November 2012).